What it is
Fragment 176-191, also written Frag 176-191 or hGH 176-191, names a short piece from the tail end of human growth hormone346. The numbers are positions along the hormone's chain of amino acids, the building blocks of proteins4. Research on this end of growth hormone, mostly in rats and mice, has looked at its effects on fat and blood sugar45.
What makes it distinct
The name doesn't pin down the molecule23. AOD-9604, the version tested in people, is described as amino acids 177 to 191 with an extra amino acid, tyrosine, added at the front, and a 2026 review says it is sometimes labelled 'hGH 176-191'12. A 2026 study from a lab that tests athletes for banned drugs lists AOD-9604 and hGH 176-191 as two separate substances3.
What the evidence shows
The studies in people in our sources were of AOD-9604, given by mouth or into a vein, and in most of them it showed no benefit for weight loss over placebo1. Whether those results apply to a product sold as Fragment 176-191 depends on whether it's the same molecule23. Under the 176-191 name itself, the studies of its effects we found are a 1978 rat study, and a 2022 study that paired it with a cancer drug and tested the mix on breast-cancer cells in a dish and in computer models47. In the rat study, a lab-made 176-191 piece briefly raised blood sugar in healthy rats and raised insulin for longer4.
Open questions
- Which molecule is in a vial labelled Fragment 176-191. One source uses the name for AOD-9604, and another treats hGH 176-191 as a separate substance23.
- Whether it raises blood sugar. The 1978 rat study found a brief rise with the 176-191 piece, while a later mouse study of AOD-9604 found none45. A 2026 review reports no significant changes in glucose tolerance, a measure of how the body handles sugar, in human studies of AOD-96042. Our sources describe studies in people only for AOD-960412.
- How long it lasts in the body (pharmacokinetics). Our sources have no measurement in people under either name12.
Worth knowing
The FDA's 2024 review and its advisory committee's December 2024 vote were about AOD-9604 by that name18. A 2026 review warns that peptides from unregulated suppliers can be mislabelled or contaminated6. Tidepath records what you tell it you're taking. It can't check what's in a vial.
Sources
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: Evaluation of AOD-9604-related bulk drug substances
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 2026;17:1822475 (PMID 42395176; full text PMC13322892)
- Mazzarino M, et al. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. Analyst 2026;151:4398-4413 (PMID 42328738)
- Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol 1978;234:E521-6 (PMID 645904)
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes 2001;25:1442-9 (PMID 11673763)
- Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness 2026;66:880-885 (PMID 41880199)
- Habibullah MM, et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther 2022;16:1963-1974 (PMID 35783198)
- FDA Final Summary Minutes, Pharmacy Compounding Advisory Committee, December 4, 2024
More in Growth-hormone fragments